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Summary.-Thirty-two variables at diagnosis of acute lymphoblastic leukaemia
(ALL) were studied in an unselected population-based series of209 children. Twelve
variables had individually a statistically significant effect on the duration of first
remission. A multivariate analysis using data on the 199 children who went into
complete remission showed that all significant variation in remission times could
be explained by only 3 variables acting simultaneously. These were the total white
blood count (WBC) at diagnosis, the Franco-American-British (FAB) classification
ofblast morphology andthepercentage oflymphoblasts with PAS+coarse granules or
blocks. A simple scoring system (for WBC add 1 if <20 x 109/1, add 2 if 20-50 x 109/1,
add 3 if >50 x 109/1; for L2 or L3 leukaemia add 1; for PAS+ <5% add 1) separated
patients into risk groups with widely different median lengths of first remission.
Application ofthe risk score improves the prediction of the outcome oftreatment, and
in clinical trials, allows more accurate stratification, less extensive data collection
and simpler analysis.
THERE HAVE BEEN few attempts to use
multivariate methods for the prediction
of prognosis in acute lymphoblastic leu-
kaemia (ALL) though its value in thyroid
cancer is well described (Byar et al., 1979).
Two previous papers (Gehan et al., 1976;
Miller et al., 1978) have shown that it is
possible to define groups of children with
different risks of relapse, and thus to
structure trials of treatment so that those
at high risk have more intensive or novel
treatment whilst those at low risk are
treated less intensively. In this way, some
patients may be spared short-term effects
of treatment such as serious infection
(Hughes, 1971) and long-term effects such
as infertility (Lendon et al., 1978) whilst
others at high risk may experience a better
response.
We examined an unselected population-
basedseriesof209 childrenwithALL, tosee
whether we could define a risk score at
diagnosis whichwouldpredictthe outcome
of treatment in those children who went
into complete remission. The length of
first remission was taken as the criterion
of response, because of almost inevitable
death following relapse in patients who
have had full conventional therapy (Corn-
bleet & Chessells, 1978). For 9 children
who died while still in first remission, the
criterion of response was the time from
achieving complete remission to death.
PATIENTS AND METHODS
Two hundred and nine consecutive patients
presenting between 1971 and 1977 with ALL
to the Royal Manchester Children's Hospital
Paediatric Oncology Unit were studied.
These children, aged between 3 months and
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16 years, represented about 95% of all
children presenting with ALL in the region
(Draper et al., 1980). All received full con-
ventional therapy with vincristine, predniso-
lone (with or without an anthracycline and/or
L-asparaginase) for induction of remission.
Cranial irradiation and intrathecal metho-
trexate or cranio-spinal irradiation were
given, followed by 2-3 years' maintenance
therapy, whcih always contained at least
methotrexate and 6-mercaptopurine. The
regimens were usually those in current
Medical Research Council (UKALL) trials.
The haematological, biochemical and radio-
logical tests carried out have already been
described (see Table I for references).
Details for each patient were put on to
coding forms and after input to computer
were analysed in two ways:
(1) The effect of each variable (age, sex,
WBC etc.) was analysed individually by cal-
culating Kaplan-Meier remission-duration
curves, which were then compared using the
logrank test (Peto etal., 1977). For continuous
variables, a convenient number of categories
were first ofall defined, and a logrank P value
for trend calculated.
(2) A regression method (Cox, 1972) was
used for the multivariate analysis of all
variables which were significant on the log-
rank tests. Stepwise inclusion of the most
significant variable was performed until the
predictive capacity of the model (assessed by
the increase in log-likelihood) was no longer
statistically significant at the 5% level.
Details of the regression method and the
calculation of the risk score for each patient
appear in the Appendix.
RESULTS
Thirty-two variables at diagnosis which
were studied individually are shown in
Table I with the level of statistical sig-
nificance for each. Twelve had a significant
effect (P < 0.05) on the length of first
remission. Time to achieve complete
remission from the start of treatment was
also statistically significant, but this was
omitted from further analysis because this
information was obviously not available at
diagnosis.
Data for 199 children who went into
complete remission were included in a
multivariate analysis which showed that
all significant variation in duration of
first remission was explained by only 3
variables acting simultaneously. These
were, in order of importance:
(1) initial total WBC;
(2) FAB morphological classification; and
(3) percentage of lymphoblasts with PAS+
coarse granules or blocks.
The effects ofeach variable individually
on the length of first remission are shown
graphically in Figs 1-3. Data from the 10
children not achieving complete remission
have been included in these graphs be-
cause it is also worth noting the additional
effect each variable had on the percentage
of children achieving complete remission.
This percentage is the point on the vertical
axis where each graph starts.
For use in the multivariate analysis the
prognostic variables were defined in the
following way:
(1) Z1 =logarithm ofthe total WBC*;
(2) Z2=FAB morphological classification:
0 for Ll, I for L2 orL3;
(3) Z3=logarithm of 1+ % lymphoblasts
with PAS+ coarse granules or blocks*.
All 3 variables were significantly cor-
related with duration of remission. The
values of the regression coefficients asso-
ciated with Zl, Z2 and Z3, and their levels
of statistical significance are shown in
Table II.
It is interesting to note that the addition
of age and low serum immunoglobulin
level as further prognostic variables gave
suggestions of possible correlation with
duration of first remission. However, the
correlations were not as strong as for the 3
variables already included and were not
quite statistically significant (P= 0 06 and
0 15 respectively). Age and low serum
immunoglobulin level were therefore not
included as determinants of remission
time.
*Logarithrm was u.secl because of the very skewed distributions. Some childrenhad no PAS+ lymphoblasts
and logarithm of zero is impossible so 1 was added to these percentages before taking logarithms.
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TABLE I.-Variables examined for possible effect on the duration of first remission
(individual logrank tests; n= 209 unless otherwise stated)
Variable
WBC (x 109/I)
FAB classification
Severe bleeding
% PAS+ lymphoblasts with coarse
granules and blocks (n= 208)
Uric acid (mM)
Time to complete remission (wks)t
Surface markers (n = 78)
Liver size (cm)
Spleen size (cm)
Blast size (n = 203) (,tm)
Ig levels (n = 196)
Age (yrs)
Renal size percentile (n =87)
CSF blasts (n = 79)
Social class (n = 201)
Haemoglobin (g/dl)
Mediastinal mass
Median
remission
No. of duration
Level patients (months)
<5
5-20
20-50
50+
LI
L2
L3
Absent
Present
0-4
5-9
10-49
50+
<0~4
0-4-0-6
0-6+
<4
4-5
5-6
6+ or never
Null
T or B
<2
3-4
5+
<2
3-4
5+
<10
10-11
12+
High
Normal
Low
<3
4-6
7+
<49
50-69
70-84
85+
Absent
Present
IV III
IV
V
<5 5-7.5
7-5-11
11+
Absent
Present
71
67
31
40
153
50
6
193
16
90
20
57
41
123
56
30
112
28
14
56
64
14
90
66
53
126
44
39
43
96
64
31
155
10
79
63
67
14
33
19
21
70
9
30
31
81
34
25
49
83
63
14
201
8
43
37
15
8
37
10
1
36
8
10
36
53
37
38
15
6
37
22
15
9
44
6
39
28
15
36
18
13
38
33
13
30
30
5
36
37
12
38
38
9
22
34
6
16
35
34
20
51
37
31
22
8
29
8
P Reference
<<0.0001*
<0-0001* Hann et al., 1979a
0-0001*
0.0002* Hann et al., 1979a
0.0003*
0.002*
0.002* Kumar et al., 1979
0.004*
0.005*
0-005* Hann et al., 1979a
0.008* Hann et al., 1980
0.014*
0-036* Hann et al., 1981
0-07
0-1
0.1
0-2
59
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TABLE I (cont.)
Variable Level
Marrow reticulin (n=83) Normal
Increased
% Cells in S phase (n=44) < 5
6+
Lymph-node size (n= 205) (cm) < 1
1-2
3+
Weight percentile (n= 208) 3
10
25
50
75
90
97
Racial group Caucasian
Asian
Other
Platelets ( x 109/1) < 25
25-50
50-100
100+
% Marrow blasts < 60
60-80
80+
% PAS+ lymphoblasts with fine
granules and blocks (n= 202) <10
10-19
20+
Height percentile (n = 208) 3
10
25
50
75
90
97
% Blasts vacuolated < 10
10-19
20-49
50-74
75+
Bone involvement (n= 163) None
Minimal
1-2
3-5
6+
Bone pain Nil
Mild
Moderate
Severe
Sex Boys
Girls
Urea (mM) < 7
7+
Serious infection Absent
Present
% Oil Red 0 cytochemical stain (n= 96) < 10
10+
* Statsitically significant, P <0-05.
t Not available at diagnosis.
No. of
patients
28
55
18
26
39
119
47
22
23
62
56
24
17
4
194
9
6
106
48
35
20
14
28
167
134
32
36
15
24
46
59
33
21
10
108
28
35
18
16
23
33
26
19
62
146
14
20
29
122
87
165
44
181
28
76
20
Median
remission
duration
(months)
41
14
34
15
36
34
15
31
20
18
39
25
60+
42
33
18
10
25
31
42
22
43
44
23
22
38
29
39
35
31
19
32
22
23
28
15
33
60+
36
26
38
17
11
39
26
17
28
43
34
26
30
33
32
18
26
37
P Reference
0-2 Hann et al., 1978
0*3 Scarffe et al., 1980
0*3
0*3
0 3
0*4
0-4
0.5 Hann et al., 1979a
0*5
0 5 Hann et al., 1979a
0-2 Hann et al., 1979b
0-6 Hann et al., 1979b
0*7
0*9
1.0
1-0 Hann et al., 1979a
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FIG. 1.-Effect of WBC (x 109/1) at diagnosis
on duration of first remission. P for trend
< 0-0001.
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FIG. 3.-Effect of % PAS+ lymphoblasts with
coarse granules and blocks on duration of
first remission. P= 0-0002.
TABLE II.-Results of the multivariate
regression analysis
A(t) = Ao(t) exp (flZl+ 132Z2+ f3Z3)
Regression
Variable coefficient
Z=log WBC pi = 0-875
Z2=FAB morphological
classification
0 for LI, I for L2 or L3 P2=0 709
Z3=log 1 +% PAS+
lymphoblasts with coarse
granules and blocks /3= -0-38
p
< 0-00001
<0-001
39 <0-002
TABLE III.-Prognosis in risk groups
Ll
(153pts)
Risk
group
1L2 I
150 pts) II
III
IV
1 3 5
Years
FIG. 2.-Effect of FAB morphological classifi-
cation (LI, L2 or L3) on duration of first
remission. P < 0-0001.
Risk
score
1
2
3
4 or 5
Number
of
children
(%)
69 (35)
56 (28)
48 (24)
28 (14)
Observed
median
duration
offirst
remission
(mths)
112+
38
10
8
% still
in first
remission
at 2 years
81
61
32
11
Each patient's risk score (see Appendix)
was calculated and the range of scores
was from -1 to 3-2. For routine use the
risk score is difficult to calculate, but an
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alternative approximate score can be
easily found by using the following simple
rule. (The equivalence of the exact and
approximate scoring systems is shown in
the Appendix.)
WVBC: < 20 x 109/1 add 1
20-50 x 109/1 add 2
r50x109/l add3
FAB type: L2 or L3 add 1
PAS+ less than 50 add 1
Four risk groups were formed, consisting
of children with total scores of 1, 2, 3 and
4 or 5 respectively. The numbers of
children in each risk group are shown in
Table III, which also shows the observed
median durations offirst remission and the
percentage in each group still in remission
2 years after remission induction. No more
than one-third ofpatients fell into any one
risk group and, by design, patients within
each group have a similar prognosis. The
value offorming risk groups is also demon-
strated by the remission curves shown in
Fig. 4.
100-
U' 1(69pts)
50
Il(56pts)
WI(28pts) I[(4bpts)
0
0 1 2 3 4 5
Years
Fie.. 4.-Duration of first remission in eacei
risk group.
To illustrate the use of the prognostic
scoring system, consider one of the chil-
dren in this study (MR), a boy aged 7
years who had a moderately high initial
WBC of 15-8 x 109/1 at diagnosis. His
disease was classed L2 according to the
FAB morphological classification and 2%
of his lymphoblasts contained PAS+
coarse granules or blocks. His risk score
would therefore be 1 for WBC + I for FAB
classification + 1 for 00 PAS positivity = 3.
It is relevant to note that in fact he was in
complete remission for only 5 months, and
although a second remission was induced
he died a year later. If the conventional
criterion of WBC less than or more than
20 x 109/1 had been used, this boy would
have fallen into the "good risk" group. By
contrast, SS is a girl aged 4 years who had
an initial WBC of 44 x 109/1 at diagnosis,
LI leukaemia, and 86% PAS+. In spite
of her high initial WBC, which conven-
tionally would put her into a "poor risk"
group, her risk score is only 2, and her
first remission lasted 6 years.
Potentially, the largest contribution to
the total risk score comes from the initial
WBC. This is not surprising since WBC is
the most important single factor. However,
its contribution may be outweighed by
other factors. For example a child with
L2 or L3 leukaemia and less than 500 of
lymphoblasts with PAS+ coarse granules
or blocks would already have a score of 2,
and even a low initial WBC (normally a
very favourable prognostic feature) would
be enough to place him in Risk Group III,
which has an estimated median time in
first remission ofonly 10 months.
DISCUSSION
There are many published reports of
prognostic factors in acute leukaemia (see
Seminars in Oncology, 3 (3), 1976 for a
recent review). Most involve small num-
bers of patients, too few factors analysed
and failure to take into account inter-
relationships between factors. No previous
studies have been population-based. Some
have analysed children and adults to-
gether (e.g. Bernard et al., 1975) and even
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acute myeloid leukaemia with ALL,
despite the known differences between
these diseases (Gehan et al., 1976). We
investigated an unselected population-
based group of children with ALL who
received full conventional treatment. in-
cluding CNS prophylaxis, at one institu-
tion under the care of one physician
(PMJ). This study shouldreflectthehetero-
geneity of the disease and help to clear up
much of the controversy over some prog-
nostic factors.
Most published reports have shown that
the prognostic factor of prime importance
in ALL is a measurement of leukaemic
mass, usually represented by the WBC and
degree of organomegaly (Simone, 1975).
The association of these factors with each
other is also well known, but the fact that
other mass factors have no separate prog-
nostic significance when correlations with
WBC are taken into account has not been
fully appreciated. We have shown that
although hepatomegaly and splenomegaly
achieve prognostic significance when
assessed individually, they have no inde-
pendent significance in a multivariate
analysis which includes WBC. Immuno-
logical blast surface markers also have a
significant effect on prognosis when exam-
ined in isolation in our series, and in
others (Greaves et al., 1977; Chessells
et al., 1977), but this significance was not
maintained in a multivariate analysis,
because of the close association between
T-cell disease and high WBC. Children
with B-cell disease may well have very
poor prognosis (Flandrin et al., 1975) but
there were too few patients in our series for
separate analysis.
FAB classification
Various attempts have been made to
classify ALL by morphological appearance
(Mathe et al., 1973; Flandrin & Bernard,
1975). TheFranco-American-British class-
ification (FAB, 1976) divides lympho-
blasts into LI, L2 and L3 subtypes, the
criteria being blast size as well as cyto-
plasmic and nuclear features. The L3 type
corresponds to B-cell leukaemia, but there
has been no consistent relationship be-
tween LI, L2 and other immunological
subtypes (Tsukimoto et al., 1976). We
found the L2 subtype had larger blasts
than LI and a higher percentage of cells
in S phase (Hann et al., 1979a). These
patients may thus have a larger tumour
growth fraction, and this maybethereason
for the worse prognosis in the L2 subtype.
PAS score
PAS score has previously been shown to
be a significant factor in the prognosis of
childhood ALL (Willoughby & Laurie,
1968; Lilleyman et al., 1979; Hann et al.,
1979a). We found an association between
low PAS score, L2 subtype and mediastinal
mass, providing further evidence of a "sar-
comatous" type of leukaemia.
In spite of a correlation with WBC as
well, the multivariate analysis showed that
the percentage of lymphoblasts with
PAS+ coarse granules and blocks was a
significant determinant of remission dura-
tion which acted independently of other
prognostic variables.
Risk score
We have constructed a simple risk score
at diagnosis of childhood ALL based on
the FAB classification, WBC, and %
PAS+ coarse granules or blocks. This risk
score accurately predicts the subsequent
prognosis of children who achieve a com-
plete remission while the categories for
WBC (< 20x 109/1, 20-50x 109/1 and
> 50 x 109/1) conform to the usual clinical
subdivisions of this variable.
For routine clinical use it is probably
preferable to combine patients with risk
scores 4 and 5 into a single Group IV. The
largest group, Group I, contains only
about one third of children. The observed
median duration of first remission varied
from only 8 months in Group IV to more
than 9 years in Group I. This remarkable
13-fold difference in prognosis is probably a
little exaggerated, because the scoring
system which is optimal for this series is
unlikely to be optimal in other series.
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However, when used in other series the
predictive power of the score should still
be very high.
Risk score in clinical trial design
There are 3 applications of our risk
score in clinical trial design. Firstly, many
trials in childhood ALL are designed
specifically for "good-" or "bad-" prog-
nosis patients, assignment usually being
to the latter group if the WBC is over
20 x 109/1 or ifmediastinal mass is present.
Our results have shown however that
the effect of a favourable or unfavourable
WBC can be outweighed by other factors,
and therefore a subdivision of patients
based on the risk score would be more
likely to produce groups consisting of
patients with roughly the same prognosis.
The risk scores we have demonstrated
should therefore be of value in idcentifying
more accurately patients with good and
bad prognosis for whom different trials
may be designed; as when some poor-
prognosis patients might be randomized to
receive novel types of treatment, while
somegood-prognosispatientsmightreceive
less-toxic therapy.
Secondly, greater comparability oftreat-
ment groups has been achieved in many
trials through randomization stratified by
important prognostic variables. If strati-
fication is used at all, practical reasons
usually restrict it to one or at the most 2
variables, whereas our analysis has shown
that in childhood ALL 3 prognostic
variables are required to explain all the
significant variation in remission times.
Because randomization stratified by risk
group is equivalent to stratification by the
3 prognostic variables which comprise the
risk score, itprovides a simple andeffective
means of ensuring that treatment groups
are as similar as possible in all important
respects.
Lastly, in deciding what variables to
record at diagnosis of ALL, it is suggested
that WBC, FAB classification, % PAS+
and a few other key variables such as age,
sex, serum immunoglobulin levels and sur-
face markers should suffice. Most other
variables may be dispensed with in the
interests of simplicity.
Risk score in clinical trial analysis
Adjustment of a treatment comparison
(or any other) to remove the simultaneous
influence of other prognostic variables is
one of the most useful features of the log-
rank method (Peto et al., 1977). In prac-
tice, adjustment for more than 3-4
variables is difficult and inefficient. How-
ever, adjustment by the single variable,
risk group, is equivalent to simultaneous
adjustment for the 3 prognostic variables
ofwhich the risk score is comprised, while
being much simpler to carry out. Finally,
the risk groups we have defined can be
used to see whether a difference in out-
come between two treatment groups in a
clinical trial is the same in all sub-groups
of patients. For example, the difference
might have one value in the good-prog-
nosis patients and another (perhaps even
in the reverse direction) in the patients
with bad prognosis. A simple and effective
way in which this can be done is to exam-
ine the treatment difference within each
risk group separately.
Clinical use of the risk score
The risk score is simple and quick to
work out and gives an accurate prediction
of outcome. It is hoped that it will be of
great value to clinicians advising parents
ofa newly diagnosed child with ALL.
We wish to record our thanks to Mrs R. Hannon
for typing the manuscript.
APPENDIX
At any time, t, after remission induction a
certain number of patients may relapse. The
hazard function at time t is defined as the
chance of relapsing on Day t among patients
in remission on Day t. An undefined hazard
function Ao(t) is taken to represent a standard
hazard function, and the assumption of the
Cox regression model is that the hazard
function A(t) corresponding to a set (Z1, Z2,
... , zp) ofvalues ofthe prognostic variablesis
then just a multiple of the standard hazard
function. This multiple is ea where a=Zi,1+
Z2f/2+.. . +Zpfp and so the form of the Cox
regression model is A(t) =ea Ao(t).
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Each regression coefficient, ,B, in the
equation reflects the net effect of the corres-
ponding variable Z on the hazard function
Ao(t) after the effects of all other variables
have been accounted for. For each patient the
value of Zl/l+Z2/2+. . .+Zp/pp can be re-
garded as a "risk score", the higher the value
the greater being the probability of relapse
and the worse the prognosis.
Examination of the regression coefficients
and variables in the risk-score equation sug-
gested that a much simpler scoring system
might have similar predictive power. It was
found empirically that the simple risk score
described in the text is for most children in
the series the nearest integer to 1+ 1 6 x
exact risk score, while the limits used for
allocating children to the different risk groups
conform to well established clinical sub-
divisions. The logrank x2 for trend obtained
by comparing actual prognosis in the four
risk groups was statistically highly significant
(X2=61*07, d.f. =1,P<000001) and was con-
sistent with the overall increase in log-like-
lihood (30.87, X2=61-74, d.f.=3,P<000001)
obtained in the multivariate regression
analysis.
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